 Michael Knitz
Concepts (94)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 13 | 2024 | 561 | 2.390 |
Why?
| | T-Lymphocytes, Regulatory | 5 | 2026 | 411 | 0.910 |
Why?
| | Immunotherapy | 5 | 2025 | 667 | 0.690 |
Why?
| | Radiation Tolerance | 1 | 2021 | 103 | 0.630 |
Why?
| | Tumor Microenvironment | 9 | 2025 | 735 | 0.610 |
Why?
| | Carcinoma, Pancreatic Ductal | 5 | 2025 | 293 | 0.600 |
Why?
| | Ephrin-B2 | 4 | 2024 | 45 | 0.590 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2021 | 198 | 0.560 |
Why?
| | Receptor, EphB4 | 3 | 2024 | 33 | 0.550 |
Why?
| | Dendritic Cells | 1 | 2021 | 500 | 0.520 |
Why?
| | Papillomavirus Infections | 1 | 2021 | 344 | 0.510 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2021 | 883 | 0.450 |
Why?
| | Pancreatic Neoplasms | 5 | 2025 | 928 | 0.430 |
Why?
| | Cell Line, Tumor | 6 | 2025 | 3551 | 0.310 |
Why?
| | Mice | 16 | 2026 | 18357 | 0.300 |
Why?
| | CD8-Positive T-Lymphocytes | 5 | 2026 | 923 | 0.280 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 3 | 2023 | 82 | 0.260 |
Why?
| | Hepatocyte Nuclear Factor 1-alpha | 1 | 2026 | 21 | 0.230 |
Why?
| | Interleukin-15 | 1 | 2026 | 95 | 0.220 |
Why?
| | Interleukin-2 | 2 | 2023 | 440 | 0.220 |
Why?
| | Adenocarcinoma | 2 | 2023 | 926 | 0.220 |
Why?
| | Animals | 16 | 2026 | 38100 | 0.210 |
Why?
| | PPAR alpha | 1 | 2024 | 55 | 0.210 |
Why?
| | Oleic Acid | 1 | 2024 | 40 | 0.210 |
Why?
| | Calcitonin Gene-Related Peptide | 1 | 2024 | 40 | 0.200 |
Why?
| | Interleukin-7 | 1 | 2024 | 66 | 0.200 |
Why?
| | Spiral Cone-Beam Computed Tomography | 1 | 2023 | 5 | 0.200 |
Why?
| | STAT3 Transcription Factor | 2 | 2022 | 206 | 0.190 |
Why?
| | Epithelial-Mesenchymal Transition | 2 | 2024 | 220 | 0.190 |
Why?
| | Tumor Burden | 2 | 2021 | 325 | 0.190 |
Why?
| | Mice, Knockout | 4 | 2026 | 3130 | 0.190 |
Why?
| | Vasculitis | 1 | 2023 | 69 | 0.180 |
Why?
| | Sentinel Lymph Node | 1 | 2022 | 49 | 0.180 |
Why?
| | Radioimmunotherapy | 1 | 2021 | 25 | 0.170 |
Why?
| | Combined Modality Therapy | 2 | 2022 | 1270 | 0.170 |
Why?
| | STAT1 Transcription Factor | 1 | 2021 | 66 | 0.170 |
Why?
| | Mice, Inbred BALB C | 2 | 2021 | 1261 | 0.170 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2021 | 23 | 0.170 |
Why?
| | ADAM10 Protein | 1 | 2021 | 29 | 0.170 |
Why?
| | Basic-Leucine Zipper Transcription Factors | 1 | 2021 | 43 | 0.170 |
Why?
| | Lymphocyte Depletion | 1 | 2021 | 132 | 0.160 |
Why?
| | Receptor, Anaphylatoxin C5a | 1 | 2021 | 35 | 0.160 |
Why?
| | Gamma Rays | 1 | 2021 | 57 | 0.160 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2021 | 78 | 0.160 |
Why?
| | Receptors, Complement | 1 | 2021 | 123 | 0.160 |
Why?
| | Complement Inactivating Agents | 1 | 2021 | 74 | 0.150 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 153 | 0.150 |
Why?
| | Radiation Injuries | 1 | 2021 | 149 | 0.150 |
Why?
| | Cell Proliferation | 3 | 2021 | 2514 | 0.140 |
Why?
| | Mice, Inbred C57BL | 4 | 2026 | 5992 | 0.140 |
Why?
| | Fibrosis | 1 | 2021 | 561 | 0.140 |
Why?
| | Repressor Proteins | 1 | 2021 | 429 | 0.130 |
Why?
| | Membrane Proteins | 2 | 2021 | 1166 | 0.130 |
Why?
| | Glioblastoma | 1 | 2020 | 354 | 0.120 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2020 | 1450 | 0.100 |
Why?
| | T-Lymphocytes | 1 | 2021 | 1997 | 0.100 |
Why?
| | Biomarkers, Tumor | 1 | 2020 | 1329 | 0.100 |
Why?
| | Phenotype | 1 | 2021 | 3170 | 0.090 |
Why?
| | Humans | 16 | 2026 | 145750 | 0.090 |
Why?
| | Tumor Cells, Cultured | 2 | 2021 | 887 | 0.070 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2021 | 936 | 0.060 |
Why?
| | Cell Movement | 2 | 2021 | 961 | 0.060 |
Why?
| | Survival Rate | 2 | 2021 | 2094 | 0.060 |
Why?
| | Fenofibrate | 1 | 2024 | 28 | 0.050 |
Why?
| | Cone-Beam Computed Tomography | 1 | 2023 | 32 | 0.050 |
Why?
| | CA-19-9 Antigen | 1 | 2023 | 34 | 0.050 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2023 | 177 | 0.050 |
Why?
| | Neoplasm Metastasis | 1 | 2024 | 688 | 0.040 |
Why?
| | Apoptosis | 2 | 2021 | 2443 | 0.040 |
Why?
| | Prognosis | 2 | 2021 | 4329 | 0.040 |
Why?
| | Lymph Node Excision | 1 | 2022 | 173 | 0.040 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2023 | 266 | 0.040 |
Why?
| | Fatty Acids | 1 | 2024 | 457 | 0.040 |
Why?
| | Complement C3 | 1 | 2021 | 187 | 0.040 |
Why?
| | Forkhead Transcription Factors | 1 | 2021 | 209 | 0.040 |
Why?
| | Neoadjuvant Therapy | 1 | 2023 | 467 | 0.040 |
Why?
| | Signal Transduction | 2 | 2024 | 5223 | 0.040 |
Why?
| | Dexamethasone | 1 | 2021 | 365 | 0.040 |
Why?
| | Neoplasm Invasiveness | 1 | 2020 | 508 | 0.030 |
Why?
| | Mice, Nude | 1 | 2020 | 680 | 0.030 |
Why?
| | Killer Cells, Natural | 1 | 2021 | 481 | 0.030 |
Why?
| | Software | 1 | 2023 | 680 | 0.030 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2024 | 1146 | 0.030 |
Why?
| | Phosphorylation | 1 | 2020 | 1708 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2021 | 835 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2023 | 3416 | 0.030 |
Why?
| | Disease Progression | 1 | 2022 | 2865 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2024 | 4569 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 1969 | 0.020 |
Why?
| | Inflammation | 1 | 2023 | 2883 | 0.020 |
Why?
| | Time Factors | 1 | 2021 | 7133 | 0.020 |
Why?
| | Female | 3 | 2025 | 79025 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2023 | 11793 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2023 | 17322 | 0.010 |
Why?
|
|
Knitz's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|